HK1200176A1 - Human inding molecules capable of inding to and neutralizing influenza viruses and uses thereof - Google Patents
Human inding molecules capable of inding to and neutralizing influenza viruses and uses thereofInfo
- Publication number
- HK1200176A1 HK1200176A1 HK15100646.1A HK15100646A HK1200176A1 HK 1200176 A1 HK1200176 A1 HK 1200176A1 HK 15100646 A HK15100646 A HK 15100646A HK 1200176 A1 HK1200176 A1 HK 1200176A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- inding
- human
- influenza viruses
- molecules capable
- neutralizing influenza
- Prior art date
Links
- 230000003472 neutralizing effect Effects 0.000 title 1
- 241000712461 unidentified influenza virus Species 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6839—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses
- A61K47/6841—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses the antibody targeting a RNA virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/11—Orthomyxoviridae, e.g. influenza virus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261608414P | 2012-03-08 | 2012-03-08 | |
EP12158525 | 2012-03-08 | ||
PCT/EP2013/054606 WO2013132007A1 (en) | 2012-03-08 | 2013-03-07 | Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1200176A1 true HK1200176A1 (en) | 2015-07-31 |
Family
ID=49115966
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15100646.1A HK1200176A1 (en) | 2012-03-08 | 2015-01-20 | Human inding molecules capable of inding to and neutralizing influenza viruses and uses thereof |
Country Status (19)
Country | Link |
---|---|
US (5) | US8834881B2 (ko) |
EP (1) | EP2822968B1 (ko) |
JP (1) | JP6328061B2 (ko) |
KR (1) | KR102050615B1 (ko) |
CN (2) | CN108640989B (ko) |
AR (1) | AR091316A1 (ko) |
AU (2) | AU2013229488B2 (ko) |
CA (1) | CA2865594C (ko) |
DK (1) | DK2822968T3 (ko) |
EA (1) | EA028433B1 (ko) |
ES (1) | ES2664625T3 (ko) |
HK (1) | HK1200176A1 (ko) |
MX (1) | MX360056B (ko) |
MY (1) | MY170407A (ko) |
NZ (1) | NZ628382A (ko) |
PH (2) | PH12014501776B1 (ko) |
SG (1) | SG11201405226TA (ko) |
TW (1) | TWI628190B (ko) |
WO (1) | WO2013132007A1 (ko) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX357009B (es) | 2011-11-28 | 2018-06-22 | Crucell Holland Bv | Vacunas contra el virus de la influenza y sus usos. |
WO2013086052A2 (en) | 2011-12-05 | 2013-06-13 | Trellis Bioscience, Llc | Antibodies useful in passive influenza immunization |
MX360056B (es) | 2012-03-08 | 2018-10-19 | Janssen Vaccines & Prevention Bv | Moléculas de unión humanas que pueden unirse a los virus de la influenza b y neutralizarlos, y sus usos. |
US9969794B2 (en) | 2012-05-10 | 2018-05-15 | Visterra, Inc. | HA binding agents |
WO2014152946A2 (en) | 2013-03-14 | 2014-09-25 | University Of Washington Through Its Center For Commercialization | Polypeptides for treating and/or limiting influenza infection |
AU2014236508A1 (en) | 2013-03-14 | 2015-09-17 | Contrafect Corporation | Composition and methods based on neutralizing antibodies delivered intranasally for enhanced therapeutic efficacy |
AU2014329609B2 (en) | 2013-10-02 | 2019-09-12 | Humabs Biomed Sa | Neutralizing anti-influenza A antibodies and uses thereof |
EP3076993A1 (en) * | 2013-12-05 | 2016-10-12 | Janssen Vaccines & Prevention B.V. | Process for preparing influenza vaccines |
WO2015120097A2 (en) * | 2014-02-04 | 2015-08-13 | Contrafect Corporation | Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof |
US10639370B2 (en) | 2014-02-04 | 2020-05-05 | Contrafect Corporation | Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof |
EP3122771A1 (en) | 2014-03-27 | 2017-02-01 | F. Hoffmann-La Roche AG | Anti-influenza b virus hemagglutinin antibodies and methods of use |
AU2015289805B2 (en) * | 2014-07-15 | 2020-06-25 | Humabs Biomed Sa | Neutralizing anti-influenza B antibodies and uses thereof |
TWI702229B (zh) | 2014-12-19 | 2020-08-21 | 美商再生元醫藥公司 | 流行性感冒病毒血球凝集素之人類抗體 |
CA2975655C (en) | 2015-02-05 | 2023-09-19 | Janssen Vaccines & Prevention B.V. | Binding molecules directed against influenza hemagglutinin and uses thereof |
AU2016261299B2 (en) * | 2015-05-11 | 2019-12-05 | Janssen Vaccines & Prevention B.V. | Influenza virus neutralizing peptidomimetic compounds |
MA48852A (fr) | 2015-05-13 | 2020-04-01 | Univ Pennsylvania | Expression médiée par aav d'anticorps anti-grippaux et leurs procédés d'utilisation |
DK3303384T3 (da) * | 2015-06-01 | 2021-10-18 | Medimmune Llc | Neutraliserende anti-influenza-bindingsmolekyler og anvendelser deraf |
JP6423550B2 (ja) * | 2015-06-03 | 2018-11-14 | シャアメン ユニバーシティ | 広域スペクトルモノクローナル抗FluB抗体およびその使用 |
JP2017062300A (ja) * | 2015-09-24 | 2017-03-30 | セイコーエプソン株式会社 | 半導体装置、システム、電子機器、及び、音声認識方法 |
WO2017083627A1 (en) | 2015-11-13 | 2017-05-18 | Visterra, Inc. | Compositions and methods for treating and preventing influenza |
SG11201805001UA (en) | 2016-01-13 | 2018-07-30 | Medimmune Llc | Method of treating influenza a |
EP3423484B1 (en) | 2016-03-01 | 2021-01-13 | Janssen Vaccines & Prevention B.V. | Human neutralizing antibodies binding to influenza b neuraminidase |
AU2017306709A1 (en) | 2016-08-05 | 2019-03-14 | Humabs, BioMed SA | Anti-o2 antibodies and uses thereof |
JP7160484B2 (ja) | 2016-10-19 | 2022-10-25 | メディミューン,エルエルシー | 抗o1抗体およびその使用 |
SG10201913833PA (en) | 2017-02-28 | 2020-03-30 | Univ Pennsylvania | Influenza vaccines based on aav vectors |
SG11201907714UA (en) | 2017-02-28 | 2019-09-27 | Univ Pennsylvania | Adeno-associated virus (aav) clade f vector and uses therefor |
JOP20190200A1 (ar) | 2017-02-28 | 2019-08-27 | Univ Pennsylvania | تركيبات نافعة في معالجة ضمور العضل النخاعي |
CA3058567A1 (en) | 2017-04-13 | 2018-10-18 | Cadila Healthcare Limited | Novel peptide based pcsk9 vaccine |
US11780907B2 (en) | 2018-01-26 | 2023-10-10 | Regeneron Pharmaceuticals, Inc. | Human antibodies to influenza hemagglutinin |
EP3820998A4 (en) * | 2018-07-11 | 2022-04-27 | Momenta Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS RELATING TO ENGINEERED FC ANTIGEN-BINDING ANTI-PD-L1 DOMAIN CONSTRUCTS |
AU2020248404A1 (en) | 2019-03-25 | 2021-09-30 | Visterra, Inc. | Compositions and methods for treating and preventing influenza |
WO2021195326A1 (en) * | 2020-03-26 | 2021-09-30 | Vanderbilt University | Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2) |
WO2021201677A1 (en) | 2020-04-01 | 2021-10-07 | Kiadis Pharma Intellectual Property B.V. | Compositions and methods targeting influenza |
BR112022021789A2 (pt) | 2020-04-27 | 2023-03-07 | Twist Bioscience Corp | Bibliotecas de ácido nucléico variantes para coronavírus |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
NL9101953A (nl) | 1991-11-21 | 1993-06-16 | Seed Capital Investments | Testinrichting omvattende een plaat met een veelvoud van putjes met een bijbehorende doseerinrichting, alsmede een kit die deze inrichtingen omvat en toepassing van de inrichtingen. |
US6248780B1 (en) | 1998-10-01 | 2001-06-19 | Duquesne University Of The Holy Ghost | Compounds for the treatment of estrogen-dependent illnesses and methods for making and using the same |
SI1533380T1 (sl) | 1999-04-15 | 2010-03-31 | Crucell Holland Bv | Proizvajanje rekombinantnega proteina v človeški celici ki obsega vsaj en protein E adenovirusa |
DK1402025T3 (da) | 2001-06-15 | 2006-06-06 | Crucell Holland Bv | Kimære fager |
US7135174B2 (en) * | 2002-01-07 | 2006-11-14 | Amgen Fremont, Inc. | Antibodies directed to PDGFD and uses thereof |
EP2441471B1 (en) * | 2005-03-08 | 2014-10-08 | MedImmune, LLC | Reassortant influenza viruses |
WO2006124269A2 (en) | 2005-05-16 | 2006-11-23 | Amgen Fremont Inc. | Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders |
TW200815474A (en) | 2006-08-03 | 2008-04-01 | Astrazeneca Ab | Antibodies alphaVbeta6 and uses thereof |
WO2008028946A2 (en) | 2006-09-07 | 2008-03-13 | Crucell Holland B.V. | Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof |
US8846867B2 (en) * | 2007-06-26 | 2014-09-30 | The Trustees Of The University Of Pennsylvania | Isolation of anti-desmoglein 1 antibodies by phage display of pemphigus foliaceus autoantibodies |
FR2921928B1 (fr) * | 2007-10-08 | 2011-03-04 | Sanofi Pasteur | Anticorps monoclonaux specifiques de l'hemagglutinine du virus grippal |
JP2011528902A (ja) * | 2008-07-25 | 2011-12-01 | インスティテュート・フォー・リサーチ・イン・バイオメディシン | 抗a型インフルエンザウイルス中和抗体およびその使用 |
EP2179811B1 (en) | 2008-10-21 | 2018-10-03 | Agie Charmilles SA | Method and apparatus for controlling an electric discharge machining process |
PT2842573T (pt) | 2008-11-07 | 2017-12-04 | Galaxy Biotech Llc | Anticorpos monoclonais para o recetor 2 do factor de crescimento de fibroblastos |
US8975378B2 (en) * | 2008-12-25 | 2015-03-10 | Osaka University | Human anti-human influenza virus antibody |
US8470327B2 (en) | 2009-05-11 | 2013-06-25 | Crucell Holland B.V. | Human binding molecules capable of neutralizing influenza virus H3N2 and uses thereof |
AU2010254136B2 (en) * | 2009-05-26 | 2016-09-29 | Mount Sinai School Of Medicine | Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof |
US8926976B2 (en) | 2009-09-25 | 2015-01-06 | Xoma Technology Ltd. | Modulators |
EP2814841A4 (en) * | 2012-01-31 | 2015-06-17 | Univ Osaka | HUMAN MONOCLONAL ANTIBODIES FOR WIDE PROTECTION AGAINST INFLUENZA B VIRUS AND METHOD OF USE THEREOF |
MX360056B (es) * | 2012-03-08 | 2018-10-19 | Janssen Vaccines & Prevention Bv | Moléculas de unión humanas que pueden unirse a los virus de la influenza b y neutralizarlos, y sus usos. |
-
2013
- 2013-03-07 MX MX2014010755A patent/MX360056B/es active IP Right Grant
- 2013-03-07 WO PCT/EP2013/054606 patent/WO2013132007A1/en active Application Filing
- 2013-03-07 EA EA201491656A patent/EA028433B1/ru not_active IP Right Cessation
- 2013-03-07 CA CA2865594A patent/CA2865594C/en active Active
- 2013-03-07 MY MYPI2014702487A patent/MY170407A/en unknown
- 2013-03-07 NZ NZ628382A patent/NZ628382A/en not_active IP Right Cessation
- 2013-03-07 DK DK13708411.7T patent/DK2822968T3/en active
- 2013-03-07 JP JP2014560375A patent/JP6328061B2/ja active Active
- 2013-03-07 AU AU2013229488A patent/AU2013229488B2/en active Active
- 2013-03-07 SG SG11201405226TA patent/SG11201405226TA/en unknown
- 2013-03-07 US US13/789,284 patent/US8834881B2/en active Active
- 2013-03-07 KR KR1020147025832A patent/KR102050615B1/ko active IP Right Grant
- 2013-03-07 CN CN201810486503.2A patent/CN108640989B/zh active Active
- 2013-03-07 EP EP13708411.7A patent/EP2822968B1/en active Active
- 2013-03-07 ES ES13708411.7T patent/ES2664625T3/es active Active
- 2013-03-07 CN CN201380012721.8A patent/CN104169298B/zh active Active
- 2013-03-08 AR ARP130100759 patent/AR091316A1/es active IP Right Grant
- 2013-03-08 TW TW102108417A patent/TWI628190B/zh not_active IP Right Cessation
- 2013-10-10 US US14/051,365 patent/US8852595B2/en active Active
-
2014
- 2014-07-03 US US14/323,908 patent/US9005621B2/en active Active
- 2014-08-07 PH PH12014501776A patent/PH12014501776B1/en unknown
- 2014-10-13 US US14/513,162 patent/US9200064B2/en active Active
-
2015
- 2015-01-20 HK HK15100646.1A patent/HK1200176A1/xx not_active IP Right Cessation
- 2015-09-17 US US14/857,587 patent/US20160002318A1/en not_active Abandoned
- 2015-11-09 PH PH12015502553A patent/PH12015502553A1/en unknown
-
2018
- 2018-03-07 AU AU2018201647A patent/AU2018201647B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1200176A1 (en) | Human inding molecules capable of inding to and neutralizing influenza viruses and uses thereof | |
HK1202123A1 (en) | Human antibodies to fel d1 and methods of use thereof fel d1 | |
HK1213591A1 (zh) | 生物粘合劑的製備和應用 | |
HK1200740A1 (en) | Combination therapy of antibodies against human csf-1r and uses thereof csf-1r | |
HK1206037A1 (en) | Human antibodies to gfr3 and methods of use thereof gfr3 | |
EP2805287A4 (en) | USE OF RECOGNITION OF HUMAN ENTRY TO PREVENT CONTAMINATION | |
GB201506561D0 (en) | Treatment of amblyopia | |
ZA201501674B (en) | Use of semaphorin-4d binding molecules to promote neurogenesis following stroke | |
PL2892556T3 (pl) | Kompozycje i sposoby odnoszące się do leczenia chorób | |
ZA201501601B (en) | Virus purification and formulation process | |
ZA201408128B (en) | Etract of greyia radlkoferi and use thereof | |
EP2751126A4 (en) | USE OF HDL MOLECULES FOR THE TREATMENT AND PREVENTION OF PROINFLAMMATORY SUFFERING | |
PL2846806T3 (pl) | Leczenie depresji oddechowej | |
GB201207907D0 (en) | Treatment of depression | |
IL234446B (en) | Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof | |
ZA201309304B (en) | Human binding molecules capable of neutralizing influenza a viruses of phylogenetic group 1 and phylogenetic group 2 and influenza b viruses | |
ZA201203832B (en) | Preparation and purification of iodixanol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20230305 |